Modern possibilities for correcting the uric acid level and eliminating skin manifestations of gout
- Authors: Vereshchagin E.I.1, Svechnikova E.V.1,2, Arutyunyan G.B.3, Artemyeva N.O.4, Devyatova A.V.4, Sherf A.A.4
-
Affiliations:
- Russian Biotechnological University
- Polyclinic №1 of the Administrative Department of the President of the Russian Federation
- Pirogov Russian National Research Medical University
- Expert Multidisciplinary Clinic OMNIUS
- Issue: Vol 30, No 8 (2023)
- Pages: 72-75
- Section: Original articles
- URL: https://journal-vniispk.ru/2073-4034/article/view/275548
- DOI: https://doi.org/10.18565/pharmateca.2023.8.72-75
- ID: 275548
Cite item
Open Access
Access granted
Subscription Access
Abstract
Background. It is well known that blood serum elevated uric acid (UA) level is the cause of a number of chronic diseases, such as gout, as well as osteoarthritis and uric acid nephritis. As a rule, prolonged hyperuricemia is accompanied by severe skin manifestations, such as pruritus, erythema, and hypersensitivity. However, the use of drugs to correct hyperuricemia, obviously, does not solve this problem. Moreover, as is known, a number of plant extracts effectively enhance the UA clearance, helping to reduce its blood serum and tissue concentration.
Objective. Evaluation of the the effectiveness of a composition based on the components of a dietary supplement based on plant components of meadowsweet (Filipéndula ulmária) and aspen (Pópulus trémula) – Hepalit* on the blood serum UA level in patients with initially elevated UA levels.
Methods. The study involved patients with elevated serum UA levels (more than 350 µmol/L in women and 415 µmol/L in men). A total of 107 patients aged 45–65 years were examined, including 47 men (Group 1) and 62 women (Group 2). During study follow-up period, patients keep a routine diet. The herbal composition of dietary supplement consisting of micronized meadowsweet leaves (Filipéndula ulmária) and aspen bark (Pópulus trémula) was used per os at a dose of 500 mg for 30 days.
Results. Taking this herbal composition for a month provided significant decrease in the UA level in both men and women. Characteristically, this effect persisted 1 month after the end of the use of composition. Simultaneously with the decrease in UA, there were positive significant changes in triglycerides and blood sugar levels in patients with initial hypertriglyceridemia and hyperglycemia. Almost 90% of patients indicated the disappearance of such manifestations as itching, erythema and hypersensitivity, 55% – a decrease in the size of tophi. The effect was observed regardless of the location and severity of skin changes.
Conclusion. The herbal composition presented in this dietary supplement is based on meadowsweet (Filipéndula ulmária) and aspen (Pópulus trémula), can be recommended for use in patients with elevated UA levels, metabolic syndrome and gout as a component of functional nutrition or an independent herbal preparation.
Full Text
##article.viewOnOriginalSite##About the authors
E. I. Vereshchagin
Russian Biotechnological University
Email: elene-elene@bk.ru
Russian Federation, Moscow
Elena V. Svechnikova
Russian Biotechnological University; Polyclinic №1 of the Administrative Department of the President of the Russian Federation
Author for correspondence.
Email: elene-elene@bk.ru
ORCID iD: 0000-0002-5885-4872
Dr. Sci. (Med.), Head of the Department of Dermatovenereology and Cosmetology; Professor at the Department of Skin and Venereal Diseases
Russian Federation, Moscow; MoscowGrigoriy B. Arutyunyan
Pirogov Russian National Research Medical University
Email: elene-elene@bk.ru
ORCID iD: 0000-0002-9454-0854
Russian Federation, Moscow
Natalia O. Artemyeva
Expert Multidisciplinary Clinic OMNIUS
Email: elene-elene@bk.ru
ORCID iD: 0000-0002-5619-6757
Russian Federation, Moscow
Alyona V. Devyatova
Expert Multidisciplinary Clinic OMNIUS
Email: elene-elene@bk.ru
ORCID iD: 0000-0003-0498-2673
Russian Federation, Moscow
A. A. Sherf
Expert Multidisciplinary Clinic OMNIUS
Email: elene-elene@bk.ru
Russian Federation, Moscow
References
- Emmerson B.T. Effect of oral fructose on urate production. Ann Rheum Dis. 1974;33:276–80.
- Fathallah-Shaykh S.A. Cramer MT Uric acid and the kidney Pediatr Nephrol. 2014;29(6):999–1008. doi: 10.1007/s00467-013-2549-x.
- King C., Lanaspa M.A., Jensen T., et al. Uric Acid as a Cause of the Metabolic Syndrome. Contrib Nephrol. 2018;192:88–102. doi: 10.1159/000484283.
- Young H.R., Yanyan Z., Hyon K.C. The epidemiology of uric acid and fructose Semin Nephrol. 2011;31(5):410–19. doi: 10.1016/j.semnephrol.2011.08.004.
- Pergola G., Cortese F., Termine G., et al. Uric Acid, Metabolic Syndrome and Atherosclerosis: The Chicken or the Egg, Which Comes First? Endocr Metab Immune Disord Drug Targets. 2018;18(3):251–59. doi: 10.2174/1871530318666180212101548.
- Abdullah A.R., Hasan H.A., Raigangar V.L. Analysis of the relationship of leptin, high-sensitivity C-reactive protein, adiponectin, insulin, and uric acid to metabolic syndrome in lean, overweight, and obese young females. Metab Syndr Relat Disord. 2009;7(1):17–22. doi: 10.1089/met.2008.0045.
- Choi H.K., Ford E.S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–47.
- Johnson R.J., Nakagawa T., Sanchez-Lozada L.G., et al. Sugar, Uric Acid, and the Etiology of Diabetes and Obesity. Diabetes. 2013;62(10):3307–15.
- Bonakdaran S., Kharaqani B. Association of serum uric acid and metabolic syndrome in type 2 diabetes. Curr Diabetes Rev. 2014;10(2):113–17. doi: 10.2174/1573399810666140228160938.
- Lanaspa M.A., Sanchez-Lozada L.G., Choi Y.J., et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287:40732–44.
- Rho Y.H., Zhu Y., Choi H.K. The epidemiology of uric acid and fructose. Semin Nephrol. 2011;31(5):410–19. doi: 10.1016/j.semnephrol.2011.08.004).
- Luk A.J., Levin G.P., Moore E.E., et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology. 2009; 48(7):804–6. doi: 10.1093/rheumatology/kep069.
- Ogino K., Kato M., Furuse Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3:73–81.
- Lee M.H., Graham G.G., Williams K.M., Day R.O. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643–65. doi: 10.2165/00002018-200831080-00002.
- Havlik J., de la Huebra R.G., Hejtmankova K., et al. Xanthine oxidase inhibitory properties of Czech medicinal plants. J Ethnopharmacol. 2010;132(2):461–65. doi: 10.1016/j.jep.2010.08.044.
- Gainche M., Ogeron C., Ripoche I., et al. Xanthine Oxidase Inhibitors from Filipendula ulmaria (L.) Maxim. and Their Efficient Detections by HPTLC and HPLC Analyses. 2021;26(7):1939.
- Crone C., Lassen U.V. Mechanism of increased renal urate excretion during administration of salicylic acid. Acta Pharmacol Toxicol. 1955;11(4):362–66. doi: 10.1111/j.1600–0773.1955.tb03271.x.
- Oliviero F., Scanu A., Zamudio-Cuevas Y., et al. Anti-inflammatory effects of polyphenols in arthritis J Sci Food Agric. 2018;98(5):1653–59. doi: 10.1002/jsfa.8664.
- Shi Y., Williamson G Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial. Br J Nutr. 2016;115(5):800–6. doi: 10.1017/S0007114515005310.
- Chen Y., Zhao Z., Li Y., et al. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. J Phytomedicine. 2021;80:153374. doi: 10.1016/j.phymed.2020.153374.
Supplementary files
